S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Price:
10.9
CNY
-2.15%
Market Closed
Market Cap:
16B
CNY
Balance Sheet
Balance Sheet Decomposition
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co Ltd
| Current Assets | 9.6B |
| Cash & Short-Term Investments | 2.6B |
| Receivables | 1.5B |
| Other Current Assets | 5.5B |
| Non-Current Assets | 7.7B |
| Long-Term Investments | 1.8B |
| PP&E | 2.6B |
| Intangibles | 2.8B |
| Other Non-Current Assets | 488.5m |
Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Currency: CNY
Millions
Annual
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
4 187
|
4 549
|
3 597
|
1 863
|
1 216
|
2 712
|
2 933
|
2 139
|
1 766
|
1 422
|
|
| Cash |
1
|
1
|
0
|
0
|
0
|
0
|
1 480
|
1 320
|
1 766
|
1 422
|
|
| Cash Equivalents |
4 186
|
4 548
|
3 597
|
1 863
|
1 216
|
2 712
|
1 453
|
819
|
0
|
0
|
|
| Short-Term Investments |
0
|
13
|
0
|
77
|
113
|
828
|
941
|
2 014
|
500
|
1 136
|
|
| Total Receivables |
575
|
729
|
1 122
|
1 377
|
1 752
|
2 026
|
1 938
|
1 927
|
1 529
|
1 516
|
|
| Accounts Receivables |
461
|
481
|
701
|
1 084
|
1 294
|
1 659
|
1 533
|
1 618
|
1 271
|
1 183
|
|
| Other Receivables |
114
|
248
|
421
|
293
|
458
|
367
|
405
|
309
|
257
|
334
|
|
| Inventory |
570
|
585
|
1 285
|
1 659
|
2 374
|
3 168
|
4 708
|
6 844
|
6 654
|
5 394
|
|
| Other Current Assets |
1 150
|
827
|
578
|
623
|
540
|
394
|
251
|
285
|
155
|
154
|
|
| Total Current Assets |
6 482
|
6 703
|
6 583
|
5 599
|
5 996
|
9 129
|
10 770
|
12 390
|
10 604
|
9 621
|
|
| PP&E Net |
1 103
|
1 223
|
1 881
|
2 439
|
2 576
|
2 571
|
2 537
|
2 477
|
2 634
|
2 648
|
|
| PP&E Gross |
1 103
|
1 223
|
1 881
|
2 439
|
2 576
|
2 571
|
2 537
|
2 477
|
2 634
|
2 648
|
|
| Accumulated Depreciation |
216
|
321
|
516
|
705
|
900
|
1 049
|
1 261
|
1 555
|
1 868
|
2 134
|
|
| Intangible Assets |
706
|
706
|
720
|
745
|
683
|
631
|
587
|
572
|
493
|
406
|
|
| Goodwill |
2 192
|
2 342
|
2 206
|
2 317
|
2 355
|
2 203
|
2 152
|
2 351
|
2 322
|
2 357
|
|
| Note Receivable |
0
|
0
|
3
|
8
|
0
|
3
|
2
|
1
|
1
|
0
|
|
| Long-Term Investments |
1 377
|
1 485
|
2 083
|
1 985
|
3 280
|
3 999
|
2 618
|
2 464
|
2 514
|
1 823
|
|
| Other Long-Term Assets |
308
|
454
|
644
|
509
|
354
|
491
|
443
|
561
|
635
|
488
|
|
| Other Assets |
2 192
|
2 342
|
2 206
|
2 317
|
2 355
|
2 203
|
2 152
|
2 351
|
2 322
|
2 357
|
|
| Total Assets |
12 168
N/A
|
12 914
+6%
|
14 119
+9%
|
13 602
-4%
|
15 242
+12%
|
19 026
+25%
|
19 108
+0%
|
20 816
+9%
|
19 203
-8%
|
17 344
-10%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
99
|
71
|
164
|
205
|
229
|
239
|
386
|
427
|
302
|
300
|
|
| Accrued Liabilities |
74
|
85
|
122
|
230
|
184
|
222
|
203
|
199
|
191
|
167
|
|
| Short-Term Debt |
50
|
508
|
1 843
|
1 981
|
2 927
|
1 860
|
1 886
|
2 385
|
1 881
|
1 839
|
|
| Current Portion of Long-Term Debt |
607
|
1 318
|
1 572
|
482
|
1 012
|
648
|
1 414
|
1 671
|
1 782
|
567
|
|
| Other Current Liabilities |
91
|
84
|
116
|
1 764
|
615
|
644
|
903
|
893
|
831
|
826
|
|
| Total Current Liabilities |
920
|
2 066
|
3 817
|
4 663
|
4 967
|
3 613
|
4 791
|
5 576
|
4 986
|
3 699
|
|
| Long-Term Debt |
1 785
|
2 095
|
1 824
|
2 449
|
2 355
|
3 137
|
2 354
|
2 407
|
1 900
|
1 139
|
|
| Deferred Income Tax |
544
|
547
|
317
|
197
|
302
|
428
|
275
|
329
|
253
|
242
|
|
| Minority Interest |
74
|
117
|
200
|
177
|
124
|
120
|
112
|
97
|
75
|
53
|
|
| Other Liabilities |
126
|
116
|
129
|
126
|
147
|
159
|
164
|
94
|
76
|
61
|
|
| Total Liabilities |
3 449
N/A
|
4 942
+43%
|
6 288
+27%
|
7 612
+21%
|
7 895
+4%
|
7 457
-6%
|
7 697
+3%
|
8 503
+10%
|
7 290
-14%
|
5 195
-29%
|
|
| Equity | |||||||||||
| Common Stock |
800
|
1 247
|
1 247
|
1 247
|
1 247
|
1 467
|
1 467
|
1 467
|
1 467
|
1 467
|
|
| Retained Earnings |
2 139
|
2 068
|
1 898
|
2 394
|
3 411
|
4 212
|
4 184
|
4 861
|
3 931
|
4 578
|
|
| Additional Paid In Capital |
5 278
|
4 219
|
4 462
|
2 304
|
2 634
|
6 035
|
5 944
|
5 859
|
6 356
|
5 865
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
85
|
94
|
128
|
|
| Treasury Stock |
116
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
618
|
437
|
224
|
45
|
55
|
145
|
183
|
210
|
252
|
366
|
|
| Total Equity |
8 719
N/A
|
7 971
-9%
|
7 831
-2%
|
5 990
-24%
|
7 347
+23%
|
11 569
+57%
|
11 411
-1%
|
12 313
+8%
|
11 913
-3%
|
12 149
+2%
|
|
| Total Liabilities & Equity |
12 168
N/A
|
12 914
+6%
|
14 119
+9%
|
13 602
-4%
|
15 242
+12%
|
19 026
+25%
|
19 108
+0%
|
20 816
+9%
|
19 203
-8%
|
17 344
-10%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
1 274
|
1 247
|
1 247
|
1 247
|
1 247
|
1 467
|
1 467
|
1 467
|
1 467
|
1 467
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
